Back to search
Toxic-Shock Syndrome
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Toxic-Shock Syndrome trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Toxic-Shock Syndrome trials you may qualify forThis is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
The availability, effectiveness, and safety of menstrual protection represent a key public health issue. However, research on women's menstrual and sexual healt…
This Phase I, prospective, single-arm clinical study aims to evaluate the efficacy and safety of adjunctive methylene blue (MB) in patients experiencing cytokin…
Menstrual staphylococcal toxic shock is a rare but severe disease, requiring intensive care in over 80% of cases. Menstrual staphylococcal toxic shock develops…
Sepsis is one of the main causes of mortality and morbidity in an ICU setting, while the responsible microorganisms most frequently isolated are multidrug-resis…
Background: Drugs or cell therapies to treat cancer can sometimes cause cytokine release syndrome (CRS). That is, the body makes too many cytokines after treat…
Sepsis is an increasingly recognised burden to healthcare systems worldwide. Intravenous fluid therapy is a common first-line intervention recommended by intern…